MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • 2023 International Congress

    Glycated alpha-synuclein and it emerging role in early onset of Parkinson’s disease

    S. Chatterjee, H. Thakkar, A. Khairnar, R. Shah (Gandhinagar, India)

    Objective: To elucidate, the molecular mechanism underlying glycated α-Syn mediated dopaminergic (DAergic) neurodegeneration in the substantia nigra (SN) via the AGE/RAGE signaling pathway. Background: Intracytoplasmic…
  • 2023 International Congress

    Analysis of the therapeutic potential of c-Abl inhibition in Multiple System Atrophy

    M. Werner, E. Bertin, A. Simmonet, E. Noé, P. Fernagut, J. Molina, K. Lowe, E. Bezard, J. Kordower (Atlanta, USA)

    Objective: IkT-148009 is a potent selective inhibitor of non-receptor Abelson Tyrosine Kinases (c-Abl kinases).  Our recent analysis of post-mortem brain tissue from patients with Multiple…
  • 2023 International Congress

    Identification of ZYIL1, a novel NLR family pyrin domain containing 3 protein inhibitor: a potential disease modifier in Parkinson’s disorder

    A. Chatterjee (Ahmedabad, India)

    Objective: Identification and evaluation of the potential of a novel NLR family pyrin domain containing 3 (NLRP3) inflammasome inhibitor (ZYIL1) as a Parkinson’s disease (PD)…
  • 2023 International Congress

    Autosomal dominant Parkinson’s disease caused by SNCA p.E46K variant in family with Russian ancestry: A case report

    K. Senkevich, I. Miliukhina, A. Zhuravlev, M. Shumilova, M. Beletskaia, A. Tyurin, M. Grunina, A. Rybakov, J. Ahmad, F. Asayesh, A. Timofeeva, Z. Gan-Or, A. Emelyanov, S. Pchelina (Montreal, Canada)

    Objective: To report a family with autosomal dominant Parkinson’s disease (PD) with SNCA p.E46K variant. Background: Alpha-synuclein, encoded by SNCA, is a part of Lewy…
  • 2022 International Congress

    Gray matter volume of proposed brain-first and body-first Parkinson’s disease subtypes

    M. Banwinkler, V. Dzialas, M. Hoenig, T. van Eimeren (Cologne, Germany)

    Objective: The aim of this study was to test if markers of the brain-first Parkinson’s disease (PD) subtype are associated with a greater or more…
  • 2022 International Congress

    DNMT1 level and global DNA methylation in CD45+ blood cells in Parkinson’s disease

    A. Lavrinova, A. Zhuravlev, I. Miliukhina, E. Belykh, A. Tyurin, O. Berkovich, S. Pchelina, A. Emelyanov (Gatchina, Russian Federation)

    Objective: The aim of our study was to assess the alterations in DNA methyltransferase1 (DNMT1) level and global DNA methylation (5-mC) in CD45+ blood cells…
  • 2022 International Congress

    The study of clonidine growth hormone study amongst definite MSA, PD, PSP, and PAF patients to assess its feasibility as a future non-invasive biomarker

    S. Bhattacharjee, E. Vichayanrat, L. Watson, V. Iodice (London, United Kingdom)

    Objective: To analyze the sensitivity and specificity of the clonidine growth hormone (CGH) to distinguish probable multiple system atrophy (MSA) from pure autonomic failure (PAF),…
  • 2022 International Congress

    Clinical presentation of SNCA Duplication Parkinsonism in a Family Kindred

    K. Dent, M. Rochman, D. Kremens, J. Ratliff (Philadelphia, USA)

    Objective: To report phenotype variability in a family with SNCA duplication associated Parkinsonism. Background: Pathogenic variants in SNCA, the gene coding for α-synuclein, cause familial…
  • 2022 International Congress

    Myelination relevant plasma microRNA biomarkers identified via an innovative data analytic scheme for differential diagnosis of MSA, an Oligodendroglial Synucleinopathy

    CC. Lu, MC. Kuo, JW. Huang, Y-T. Tsai, H-H. Lin Wang, PJ. Kung, C-C. Wu, Y-Y. Hsueh, T. Ochiya, FKH. Phoa, S-P. Lin, R-M. Wu (Taipei, Taiwan)

    Objective: To establish an inclusive data analytic scheme to identify and characterize plasma microRNA biomarkers with pathophysiological significance for differentiating the atypical Parkinsonian, Multiple System…
  • 2022 International Congress

    IkT-148009 as a potential disease-modifying therapy in PD

    M. Werner, S. Karuppagounder, R. Rush, T. Kelly, T. Dawson, V. Dawson (Atlanta, USA)

    Objective: Modeling Parkinson’s disease in mice suggests c-Abl activation is required for PD initiation and progression, and therefore inhibition of c-Abl could be a strategy…
  • « Previous Page
  • 1
  • …
  • 31
  • 32
  • 33
  • 34
  • 35
  • …
  • 70
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley